NASDAQ:CRIS - Curis, Inc.
$1.77
 $-0.05
-2.75%
4:00PM EDT
2019-04-18
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CRIS     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 87   203. 85   241. 91  
42 stocks rank:  3. 45 K 1. 44 K 1. 05 K
# analyst opinions:  1. 00   14. 51   13. 97  
mean recommendation:  1. 00   2. 09   2. 01  

quick ratio:  2. 05   5. 27   1. 81  
current ratio:  2. 11   5. 62   2. 25  

target price low:  2. 86   84. 80   115. 21  
target price avg:  2. 86   111. 51   137. 51  
target price high:  2. 86   135. 81   157. 84  
1-yr high:  3. 05   114. 23   138. 78  
last close:  1. 77   87. 66   116. 69  
50-day avg:  1. 51   95. 54   123. 44  
200-day avg:  1. 45   94. 25   121. 11  
1-yr low:  0. 62   72. 78   98. 34  
volume:  148. 44 K 4. 11 M 8. 07 M
50-day avg volume:  728. 37 K 2. 76 M 5. 02 M
200-day avg volume:  416. 43 K 2. 92 M 4. 59 M

1-day return:  -2. 75 % -0. 41 % 0. 07 %
this week return:  -14. 49 % -5. 74 % -4. 11 %
12-wk return:  39. 37 % 1. 61 % -0. 05 %
52-wk return:  -32. 59 % 3. 12 % 8. 78 %

enterprise value (EV):  69. 89 M 48. 94 B 114. 64 B
market cap:  58. 68 M 43. 07 B 104. 73 B
EBITDA:  -29. 16 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -2. 40   4. 22   12. 73  
enterprise/revenue (EV/R):  6. 70   63. 17   12. 84  
total revenue:  10. 43 M 10. 62 B 38. 47 B
total debt:  35. 48 M 12. 24 B 16. 73 B
net income (common):  -32. 58 M 2. 20 B 4. 20 B

shares outstanding:  33. 15 M 571. 70 M 1. 24 B
shares:  24. 49 M 571. 81 M 1. 23 B
shares short:  1. 34 M 10. 17 M 13. 00 M
shares short prior month:  1. 33 M 9. 54 M 17. 33 M
short ratio:  0. 96   5. 41   3. 28  
total cash/share:  0. 73   11. 14   9. 33  
total cash:  24. 27 M 6. 71 B 7. 15 B
free cash flow:  -18. 20 M 3. 58 B 2. 96 B
operating cash flow:  -30. 07 M 4. 15 B 4. 30 B

book value:  -0. 14   12. 78   26. 92  
price/book:  -13. 01   3. 06   -1. 74  
gross profits:  -14. 55 M 8. 04 B 34. 86 B
operating margins:  -281. 29 % -725. 35 % -89. 04 %
EBITDA margins:  -279. 59 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  -139. 51 % 37. 08 % 55. 70 %

1-yr max volatility:  32. 17 % --- ---
1-yr mean volatility:  0. 01 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 98   2. 40   4. 10  
forward EPS:  -0. 85   3. 97   7. 13  
P/E:  -1. 80   13. 63   22. 72  
forward P/E:  -2. 08   -15. 95   13. 99  
PE/G:  0. 12   -1. 65   -1. 32  
growth:  -15. 50 % 127. 12 % 29. 61 %
earnings high:  -0. 18   1. 00   1. 66  
earnings avg:  -0. 18   0. 77   1. 53  
earnings low:  -0. 18   0. 50   1. 39  
revenue high:  2. 40 M 2. 68 B 10. 78 B
revenue avg:  2. 40 M 2. 59 B 10. 57 B
revenue low:  2. 40 M 2. 49 B 10. 36 B
return on assets:  -32. 98 % -2. 75 % 4. 55 %
return on equity:  -334. 15 % -18. 45 % 5. 46 %
revenue growth:  -15. 50 % 92. 86 % 18. 96 %
revenue/share:  0. 32   13. 29   55. 46  

beta (1yr vs S&P500):  1. 32   1. 25   0. 93  
sharpe (1yr):  0. 03   0. 37   0. 70  

held % insiders:  17. 28 % 6. 39 % 3. 38 %
held % institutions:  24. 15 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : CRIS
.    + 0.346 =         0.346 :: INITIAL WEIGHT
.    + 38.97 =        39.316 :: spline projection addition
.    x 1.431 =        56.278 :: industry recommendation factor
.    x 2.463 =       138.637 :: symbol recommendation factor
.    x 1.106 =       153.345 :: EV/R factor
.    x 0.997 =       152.839 :: return on assets factor
.    x 0.967 =       147.732 :: return on equity factor
.    x 0.998 =       147.503 :: revenue growth factor
.    x 2.375 =       350.343 :: current ratio factor
.    x 1.398 =       489.754 :: quick ratio factor
.    x 1.429 =       699.794 :: short ratio factor
.     x 1.87 =      1308.512 :: price-to-book factor
.    x 1.312 =      1716.408 :: 5-day avg > 200-day avg
.    x 1.257 =      2157.445 :: 5-day avg > 50-day avg
.    x 1.044 =      2251.455 :: 50-day avg > 200-day avg
.    x 2.147 =      4832.792 :: P/E weight
.    x 1.713 =      8280.117 :: PE/G factor
.    x 1.586 =     13135.177 :: beta factor
.    x 0.033 =       430.453 :: sharpe factor
.    x 1.854 =       798.164 :: target low factor
.    x 1.262 =      1007.406 :: target mean factor
.    x 1.079 =      1086.634 :: target high factor
.     x 1.31 =      1423.369 :: industry 2-weeks return factor
.    x 0.857 =      1219.578 :: "drift" penalty 2 days ago
.    x 0.882 =      1075.577 :: "drift" penalty 4 days ago
.     x 0.52 =       559.451 :: overall "drift" factor
.    x 0.678 =       379.488 :: largest single-day jump factor
.    x 0.065 =        24.626 :: low price factor
.      x 1.0 =        24.622 :: factor hist industry gain for week 16
.   cubeRoot =         2.909 :: reduced to standardize
.   - 25.939 =         0.868 :: add/subtract for performance
.                      0.868 :: FINAL WEIGHT for NASDAQ:CRIS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org